Nepafenac

Generic Name: Nepafenac

Brand Names: Ilevro, Nevanac

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O_₂

CAS Number: 78281-72-8

Unique Ingredient Identifier: 0J9L7J6V8C

Background: Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.

Indication: For the treatment of pain and inflammation associated with cataract surgery.

Associated Conditions: Inflammation, Pain

Associated Therapies: -

Clinical Trials

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Phase 4

Completed

Conditions: Treatment of Ocular Inflammation Associated With Cataract Surgery

Interventions: Drug: Nepafenac
Drug: Bromfenac

First Posted Date: 2019-03-22

Last Posted Date: 2019-04-01

Lead Sponsor: Silverstein Eye Centers

Target Recruit Count: 57

Registration Number: NCT03886779

Dropless vs. Standard Drops Contralateral Eye Study

Phase 4

Completed

Conditions: Cataract

Interventions: Drug: TriMoxiVanc
Drug: Moxifloxacin HCl 0.5%
Drug: Ilevro
Drug: Prednisolone acetate 1%

First Posted Date: 2015-08-04

Last Posted Date: 2018-02-23

Lead Sponsor: Carolina Eyecare Physicians, LLC

Target Recruit Count: 59

Registration Number: NCT02515045

Locations: 🇺🇸
Associated Eye Care, Stillwater, Minnesota, United States
🇺🇸
Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States
🇺🇸
Minnesota Eye Consultants, P.A., Bloomington, Minnesota, United States

and more 1 locations

Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort

Not Applicable

Conditions: Post Surgical Management
Pain Management
Inflamation Management

Interventions: Drug: Diclofenac
Drug: Nepafenac

First Posted Date: 2015-07-23

Last Posted Date: 2015-07-24

Lead Sponsor: Wolfson Medical Center

Target Recruit Count: 30

Registration Number: NCT02506348

Locations: 🇮🇱
The E.Wolfson Medical Center, Holon, Israel

Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification

Phase 4

Completed

Conditions: Cystoid Macular Edema
Cataract

Interventions: Drug: Nepafenac
Drug: Ketorolac

First Posted Date: 2014-03-12

Last Posted Date: 2014-03-12

Lead Sponsor: Hospital Oftalmologico de Brasilia

Target Recruit Count: 40

Registration Number: NCT02084576

Locations: 🇧🇷
Hospital Oftalmologico de Brasília, Brasilia, DF, Brazil

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes

Phase 4

Completed

Conditions: Intraocular Pressure

Interventions: Drug: nepafenac

First Posted Date: 2013-11-27

Last Posted Date: 2013-11-27

Lead Sponsor: Dr T V Patel Eye Institute

Target Recruit Count: 327

Registration Number: NCT01995890

Locations: 🇮🇳
Dr TV Patel Eye Insititute, Vadodara, Gujarat, India

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Phase 4

Terminated

Conditions: Uveitis
Macular Edema

Interventions: Drug: Nepafenac
Drug: Difluprednate
Drug: Prednisolone acetate

First Posted Date: 2013-09-11

Last Posted Date: 2021-01-13

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 9

Registration Number: NCT01939691

Locations: 🇮🇳
Aravind Eye Hospital, Pondicherry, Tamil Nadu, India

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Phase 4

Completed

Conditions: Inflammation
Pseudophakia

Interventions: Drug: Bromfenac
Drug: Nepafenac

First Posted Date: 2011-03-08

Last Posted Date: 2020-10-28

Lead Sponsor: Toyos Clinic

Target Recruit Count: 23

Registration Number: NCT01310127

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Phase 4

Completed

Conditions: Cataracts

Interventions: Drug: Bromfenac
Drug: nepafenac
Drug: Ketorolac Tromethamine

First Posted Date: 2009-11-30

Last Posted Date: 2011-08-31

Lead Sponsor: Frank A. Bucci, Jr., M.D.

Target Recruit Count: 126

Registration Number: NCT01021761

Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema

Phase 2

Completed

Conditions: Diabetic Retinopathy
Macular Edema

Interventions: Drug: Nepafenac
Drug: Polietilenglicol 400, propilenglicol
Drug: Ketorolac

First Posted Date: 2009-05-13

Last Posted Date: 2015-03-20

Lead Sponsor: Hospital Juarez de Mexico

Target Recruit Count: 84

Registration Number: NCT00900887

Locations: 🇲🇽
Virgilio Lima Gomez, Mexico, Distrito Federal, Mexico

Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation

Phase 2

Terminated

Conditions: Macular Thickening
Macular Edema

Interventions: Drug: Nepafenac
Other: Lubricant

First Posted Date: 2008-12-04

Last Posted Date: 2024-05-30

Lead Sponsor: Asociación para Evitar la Ceguera en México

Target Recruit Count: 50

Registration Number: NCT00801905

Locations: 🇲🇽
Asociacion para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico
🇲🇽
Asociación Para Evitar la Ceguera en México I.A.P., Mexico City, Mexico

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy